NASDAQ: CVACCurevac Nv Stock
$4.21-0.02 (-0.47%)
Updated Jan 10, 2025
CVAC Price
$4.21
Fair Value Price
N/A
Market Cap
$944.46M
52 Week Low
$2.22
52 Week High
$5.28
P/E
8.08x
P/B
1.23x
P/S
1.09x
PEG
N/A
Dividend Yield
N/A
Revenue
$577.96M
Earnings
$120.33M
Gross Margin
70.9%
Operating Margin
25.63%
Profit Margin
19.9%
Debt to Equity
0.18
Operating Cash Flow
$139M
Beta
1.25
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CVAC Overview
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CVAC's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
A
Value
B
Growth
C
Momentum
C
Sentiment
D
Safety
B
Financials
C
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CVAC
Ranked#17 of 556
Ranked#17 of 556
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $16.25 | A | |
| $121.41 | A | |
| $5.27 | A |
Be the first to know about important CVAC news, forecast changes, insider trades & much more!
CVAC News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CVAC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CVAC is forecast by analysts to be unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CVAC is good value based on its earnings relative to its share price (8.08x), compared to the US market average (30.06x)
P/E vs Market Valuation
CVAC is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more CVAC due diligence checks available for Premium users.
Valuation
CVAC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
8.08x
Industry
-113.93x
Market
30.06x
CVAC is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
CVAC is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
CVAC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.23x
Industry
4.88x
CVAC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CVAC's financial health
Profit margin
Revenue
$548.8M
Net Income
$375.6M
Profit Margin
68.4%
CVAC's Earnings (EBIT) of $148.15M... subscribe to Premium to read more.
Interest Coverage Financials
CVAC's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$949.1M
Liabilities
$143.9M
Debt to equity
0.18
CVAC's short-term assets ($622.04M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CVAC's short-term assets ($622.04M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CVAC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$393.4M
Investing
-$3.7M
Financing
-$1.7M
CVAC's operating cash flow ($132.77M)... subscribe to Premium to read more.
Debt Coverage Financials
CVAC vs Biotech Stocks
Curevac Nv Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.